Does Kratom Need Tighter Regulation?
MedPage Today, By Rachael Robertson
|
We’re on the cusp of another psychedelic era. But this time Washington is along for the ride
Politico, By Erin Schumaker and Katherine Ellen Foley
|
Expanding Treatment for Opioid Use Disorder
Gray TV, By Graham Ulkins
|
Black Adults, Women are less likely to get life-saving opioid treatments in US
Bloomberg, By Cristela Jones and Matthew Griffin
|
Only 1 in 5 people with opioid use disorder received medication in 2021
The Hill, By Joseph Choi
|
NIDA Director Discusses Cannabis Use Among Seniors
CNN -The Whole Story with Anderson Cooper highlighting “Weed 7: A Senior Moment”, By Sanjay Gupta
|
NIDA, NIMH Directors Describe Promise, Challenges Associated with Psychedelics Research
Psychiatric News, By Staff
|
Marijuana addiction is real. Those struggling often face skepticism
The Washington Post, By David Ovalle and Fenit Nirappil
|
NIDA Director Nora Volkow Discusses Fentanyl Overdoses
Voz de America, By Júlia Riera
|
Opioids mixed with cocaine or psychostimulants are driving more overdose deaths, CDC data show
CNN, By Deidre McPhillips
|
Using weed to improve your mental health? Not so fast, experts say
The Baltimore Banner, By Meredith Cohn and Taylor DeVille
|
How the pandemic spurred a push to expand methadone access
The Hill, By Joseph Choi
|
Could Ozempic be used to treat addiction? Studies hint yes, but questions remain
Live Science, By Rebecca Sohn
|
Nora Volkow, Director of the National Institute on Drug Abuse
The Visible Voices Podcast, By Dr. Resa E. Lewiss
|
Is Ozempic Really an Anti-Addiction Drug?
Everyday Health, By Carmen Chai
|
Xylazine present in more than 1 in 10 fentanyl overdose deaths in the US
CNN Health, By Deidre McPhillips and Nadia Kounang
|
Drug Deaths Tied to ‘Tranq’ Soar in U.S.
U.S. News and World Report, By Steven Ross Johnson
|
Home delivery of alcohol expanded during pandemic, with permanent effects on health
Health Day, By Steven Reinberg
|
AI-based analysis of social media language predicts addiction treatment dropout at 90 days
Brainpod: The Neuropsychopharmacology Podcast
|